United States · Biotechnology startup
United States · Cyclerion Therapeutics
Cyclerion Therapeutics harnesses the potential of soluble guanylate cyclase (sGC) pharmacology.
Funding reportedLast round: Post-IPO Equity
What company datasets say Cyclerion Therapeutics raised
Funding, as reported
Reported in all$222Min dollars
Rounds4
Last roundPost-IPO Equity
Last round dateMay 2023
Investors listed5
SEC Form D$222M sold, 4 filings, last May 2023
Founders and team
From Cyclerion Therapeutics's own website and the SEC filings it signed: 12 on the team.
- Jonathan ViolinChief Executive Officer
- Gan WeiChief Technology Officer
- Mark VignolaChief Financial Officer
- Matthew LeoniChief Medical Officer
- Andrew GottesdienerDirector
- Heidi HensonDirector
- Michelle PerniceDirector
- Nimish ShahDirector
- Tomas KiselakChairman
- Anjeza M. GjinoExecutive Officeri
- Cheryl M. GaultExecutive Officeri
- Peter M. HechtDirector, Executive Officeri
On the board, as filediErrol M. De SouzaOle M. IsacsonSteven M. HymanTerrance M. McGuire
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Cyclerion Therapeutics in front of investors. Or tell us what we have wrong.